NASDAQ:EFTR eFFECTOR Therapeutics (EFTR) Stock Price, News & Analysis $0.03 -0.01 (-28.33%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About eFFECTOR Therapeutics Stock (NASDAQ:EFTR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get eFFECTOR Therapeutics alerts:Sign Up Key Stats Today's Range$0.03▼$0.0450-Day Range$0.03▼$0.0552-Week Range$0.03▼$17.90Volume11,037 shsAverage Volume348,372 shsMarket Capitalization$119,011.20P/E RatioN/ADividend YieldN/APrice Target$24.00Consensus RatingBuy Company OvervieweFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.Read More… Next opportunity for crypto millions (Ad)"Uptober" is here, and it's not just a clever name. Historically, October ignites crypto's most explosive gains. This year could be off the charts. Don't let this opportunity pass you by. In crypto, timing is everything. Go here to discover the #1 crypto set to dominate Uptober. eFFECTOR Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks22nd Percentile Overall ScoreEFTR MarketRank™: eFFECTOR Therapeutics scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingeFFECTOR Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageeFFECTOR Therapeutics has received no research coverage in the past 90 days.Read more about eFFECTOR Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of eFFECTOR Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of eFFECTOR Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for EFTR. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldeFFECTOR Therapeutics does not currently pay a dividend.Dividend GrowtheFFECTOR Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for EFTR. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for eFFECTOR Therapeutics this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, eFFECTOR Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of eFFECTOR Therapeutics is held by insiders.Percentage Held by Institutions57.67% of the stock of eFFECTOR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about eFFECTOR Therapeutics' insider trading history. Receive EFTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address EFTR Stock News HeadlineseFFECTOR Therapeutics (OTC:EFTR) Stock, Insider Trading ActivityOctober 5 at 11:50 AM | benzinga.com3 Publicly Traded Companies Filing for Bankruptcy as July Kicks OffJuly 15, 2024 | investorplace.comWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.October 6, 2024 | Porter & Company (Ad)eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from NasdaqJune 24, 2024 | globenewswire.comeFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian CancerMay 20, 2024 | globenewswire.comEFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024May 9, 2024 | investorplace.comeFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | globenewswire.comeFFECTOR Therapeutics to Participate in Upcoming Investor ConferenceApril 9, 2024 | globenewswire.comSee More Headlines EFTR Stock Analysis - Frequently Asked Questions How have EFTR shares performed this year? eFFECTOR Therapeutics' stock was trading at $11.6850 at the beginning of the year. Since then, EFTR stock has decreased by 99.8% and is now trading at $0.0253. View the best growth stocks for 2024 here. How were eFFECTOR Therapeutics' earnings last quarter? eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) issued its quarterly earnings results on Monday, November, 8th. The company reported $10.50 earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.50) by $17.00. The business earned $0.43 million during the quarter. When did eFFECTOR Therapeutics' stock split? Shares of eFFECTOR Therapeutics reverse split before market open on Friday, January 12th 2024. The 1-25 reverse split was announced on Friday, January 12th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of eFFECTOR Therapeutics? Shares of EFTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings11/08/2021Today10/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EFTR CUSIPN/A CIK1828522 Webwww.locustwalkacquisitioncorp.com Phone858-925-8215FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$24.00 High Stock Price Target$24.00 Low Stock Price Target$24.00 Potential Upside/Downside+94,761.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($13.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,810,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-146.23% Debt Debt-to-Equity RatioN/A Current Ratio1.03 Quick Ratio1.03 Sales & Book Value Annual Sales$3.55 million Price / Sales0.03 Cash FlowN/A Price / Cash FlowN/A Book Value($1.94) per share Price / Book-0.01Miscellaneous Outstanding Shares4,704,000Free Float4,483,000Market Cap$119,011.20 OptionableNo Data Beta0.63 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:EFTR) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHow much money are you leaving on the table from the stocks you already own?Charles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash...Unstoppable Prosperity | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.